{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:32:54Z","timestamp":1792708374763,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173985"],"award-info":[{"award-number":["82173985"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Materials Today Bio"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.mtbio.2025.101634","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:36:02Z","timestamp":1741116962000},"page":"101634","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Oxymatrine and astragaloside IV co-loaded liposomes: Scale-up purposes and their enhancement of anti-PD-1 efficacy against breast cancer"],"prefix":"10.1016","volume":"32","author":[{"given":"Liangyin","family":"Wei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xietao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengxuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4691-4348","authenticated-orcid":false,"given":"Yuping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0864-1630","authenticated-orcid":false,"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mtbio.2025.101634_bib1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.mtbio.2025.101634_bib2","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005543","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer","volume":"10","author":"Yi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.mtbio.2025.101634_bib3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.semcancer.2019.12.003","article-title":"PD-L1 status in breast cancer: current view and perspectives","volume":"72","author":"Vranic","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"1","key":"10.1016\/j.mtbio.2025.101634_bib4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","article-title":"Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer","volume":"22","author":"Ye","year":"2023","journal-title":"Mol. Cancer"},{"issue":"7637","key":"10.1016\/j.mtbio.2025.101634_bib5","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.mtbio.2025.101634_bib6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/cac2.12291","article-title":"Cancer-associated fibroblasts in breast cancer: challenges and opportunities","volume":"42","author":"Hu","year":"2022","journal-title":"Cancer Commun."},{"issue":"Pt A","key":"10.1016\/j.mtbio.2025.101634_bib7","article-title":"Combination of oxymatrine (Om) and astragaloside IV (As) enhances the infiltration and function of TILs in triple-negative breast cancer (TNBC)","volume":"125","author":"Wang","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.mtbio.2025.101634_bib8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12951-022-01311-1","article-title":"A CFH peptide-decorated liposomal oxymatrine inactivates cancer-associated fibroblasts of hepatocellular carcinoma through epithelial-mesenchymal transition reversion","volume":"20","author":"Guo","year":"2022","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.mtbio.2025.101634_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104541","article-title":"Oxymatrine exerts organ- and tissue-protective effects by regulating inflammation, oxidative stress, apoptosis, and fibrosis: from bench to bedside","volume":"151","author":"Lan","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.mtbio.2025.101634_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s13046-018-0948-3","article-title":"Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs\/ROS\/Trx1 signalling pathway","volume":"37","author":"Jin","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.mtbio.2025.101634_bib11","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/aps.2015.24","article-title":"Anti-tumor activities of active ingredients in compound kushen injection","volume":"36","author":"Wang","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"23","key":"10.1016\/j.mtbio.2025.101634_bib12","doi-asserted-by":"crossref","first-page":"23829","DOI":"10.1021\/acsnano.3c07885","article-title":"Magnetic metal-organic framework-based nanoplatform with platelet membrane coating as a synergistic programmed cell death protein 1 inhibitor against hepatocellular carcinoma","volume":"17","author":"Guo","year":"2023","journal-title":"ACS Nano"},{"issue":"Pt B","key":"10.1016\/j.mtbio.2025.101634_bib13","article-title":"Apigenin-oxymatrine binary co-amorphous mixture: enhanced solubility, bioavailability, and anti-inflammatory effect","volume":"373","author":"Li","year":"2022","journal-title":"Food Chem."},{"issue":"24","key":"10.1016\/j.mtbio.2025.101634_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232415909","article-title":"Development of inhalable chitosan-coated oxymatrine liposomes to alleviate RSV-infected mice","volume":"23","author":"Peng","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2025.101634_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153698","article-title":"The anti-cancerous activity of adaptogenic herb Astragalus membranaceus","volume":"91","author":"Sheik","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.mtbio.2025.101634_bib16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jconrel.2022.11.049","article-title":"Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer","volume":"353","author":"Gu","year":"2023","journal-title":"J Control Release"},{"issue":"15","key":"10.1016\/j.mtbio.2025.101634_bib17","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1039\/D2TB02328H","article-title":"Combined chemo-immuno-photothermal therapy based on ursolic acid\/astragaloside IV-loaded hyaluronic acid-modified polydopamine nanomedicine inhibiting the growth and metastasis of non-small cell lung cancer","volume":"11","author":"Xu","year":"2023","journal-title":"J. Mater. Chem. B"},{"issue":"1","key":"10.1016\/j.mtbio.2025.101634_bib18","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1080\/10717544.2022.2086942","article-title":"Alendronate modified mPEG-PLGA nano-micelle drug delivery system loaded with astragaloside has anti-osteoporotic effect in rats","volume":"29","author":"Xi","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.mtbio.2025.101634_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119617","article-title":"Oxymatrine loaded nitric oxide-releasing liposomes for the treatment of ulcerative colitis","volume":"586","author":"Tang","year":"2020","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.mtbio.2025.101634_bib20","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1038\/s41467-023-41946-8","article-title":"Aromatized liposomes for sustained drug delivery","volume":"14","author":"Li","year":"2023","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.mtbio.2025.101634_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201901633","article-title":"Materials for immunotherapy","volume":"32","author":"Shields","year":"2020","journal-title":"Adv Mater"},{"key":"10.1016\/j.mtbio.2025.101634_bib22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejps.2017.03.048","article-title":"Effect of oxymatrine HSPC liposomes on improving bioavailability, liver target distribution and hepatoprotective activity of oxymatrine","volume":"104","author":"Liu","year":"2017","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.mtbio.2025.101634_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112361","article-title":"Astragaloside IV- and nesfatin-1-encapsulated phosphatidylserine liposomes conjugated with wheat germ agglutinin and leptin to activate anti-apoptotic pathway and block phosphorylated tau protein expression for Parkinson's disease treatment","volume":"129","author":"Kuo","year":"2021","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"20","key":"10.1016\/j.mtbio.2025.101634_bib24","doi-asserted-by":"crossref","first-page":"12181","DOI":"10.1021\/acs.chemrev.1c00244","article-title":"Lipids and lipid derivatives for RNA delivery","volume":"121","author":"Zhang","year":"2021","journal-title":"Chem Rev"},{"issue":"7","key":"10.1016\/j.mtbio.2025.101634_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076615","article-title":"Liposomes in cancer therapy: how did we start and where are we now","volume":"24","author":"Fulton","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.mtbio.2025.101634_bib26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.addr.2020.05.012","article-title":"Translational considerations in nanomedicine: the oncology perspective","volume":"158","author":"Gabizon","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2025.101634_bib27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jconrel.2017.06.003","article-title":"Nanosizing techniques for improving bioavailability of drugs","volume":"260","author":"Al-Kassas","year":"2017","journal-title":"J Control Release"},{"key":"10.1016\/j.mtbio.2025.101634_bib28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2023.07.054","article-title":"Lipid nanoparticles for siRNA delivery in cancer treatment","volume":"361","author":"El Moukhtari","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.mtbio.2025.101634_bib29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jconrel.2021.07.012","article-title":"Pilot-scale production of expansile nanoparticles: practical methods for clinical scale-up","volume":"337","author":"Colby","year":"2021","journal-title":"J Control Release"},{"issue":"3","key":"10.1016\/j.mtbio.2025.101634_bib30","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jconrel.2013.08.006","article-title":"Stability of nanosuspensions in drug delivery","volume":"172","author":"Wang","year":"2013","journal-title":"J Control Release"},{"key":"10.1016\/j.mtbio.2025.101634_bib31","article-title":"Photothermal 2D nanosheets combined with astragaloside IV for antibacterial properties and promoting angiogenesis to treat infected wounds","volume":"9","author":"Liu","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.mtbio.2025.101634_bib32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","article-title":"Liposomes: advancements and innovation in the manufacturing process","volume":"154\u2013155","author":"Shah","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.mtbio.2025.101634_bib33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jconrel.2013.10.037","article-title":"A liposomal fluorescence assay to study permeation kinetics of drug-like weak bases across the lipid bilayer","volume":"173","author":"Eyer","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.mtbio.2025.101634_bib34","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2147\/DDDT.S242493","article-title":"Oxymatrine liposomes for intervertebral disc treatment: formulation, in vitro and vivo assessments","volume":"14","author":"Wang","year":"2020","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.mtbio.2025.101634_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08982104.2022.2069809","article-title":"Rationale utilization of phospholipid excipients: a distinctive tool for progressing state of the art in research of emerging drug carriers","volume":"33","author":"Jebastin","year":"2023","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.mtbio.2025.101634_bib36","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.ijpharm.2019.06.033","article-title":"Sterically stabilized liposomes production using staggered herringbone micromixer: effect of lipid composition and PEG-lipid content","volume":"566","author":"Cheung","year":"2019","journal-title":"Int J Pharm"},{"key":"10.1016\/j.mtbio.2025.101634_bib37","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.addr.2020.06.022","article-title":"Recent advancements in liposome technology","volume":"156","author":"Filipczak","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"8","key":"10.1016\/j.mtbio.2025.101634_bib38","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1016\/j.apsb.2023.01.018","article-title":"Microfluidics for nano-drug delivery systems: from fundamentals to industrialization","volume":"13","author":"Zhang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.mtbio.2025.101634_bib39","series-title":"U. S. D. O. H. a. H. S. F. a. D. A. C. F. D. E. a. R., Lipsomes Drug Products Chemistry,manufacturing,and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation","year":"2018"},{"key":"10.1016\/j.mtbio.2025.101634_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122022","article-title":"Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: an update","volume":"624","author":"Sainaga Jyothi","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.mtbio.2025.101634_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2021.111923","article-title":"Quantitative comparison of different fluorescent dye-loaded nanoparticles","volume":"206","author":"Yang","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"issue":"8","key":"10.1016\/j.mtbio.2025.101634_bib42","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1039\/D0NA00716A","article-title":"Kinetics of nanoparticle uptake into and distribution in human cells","volume":"3","author":"\u00c5berg","year":"2021","journal-title":"Nanoscale Adv."},{"issue":"2","key":"10.1016\/j.mtbio.2025.101634_bib43","article-title":"Progress and challenges of immunotherapy in triple-negative breast cancer","volume":"1876","author":"Zhu","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"3","key":"10.1016\/j.mtbio.2025.101634_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003667","article-title":"Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer","volume":"10","author":"Wang","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.mtbio.2025.101634_bib45","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.7150\/thno.68972","article-title":"FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts","volume":"12","author":"Wu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.mtbio.2025.101634_bib46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-immunol-042617-053019","article-title":"Unraveling the complex interplay between T cell metabolism and function","volume":"36","author":"Geltink","year":"2018","journal-title":"Annu. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.mtbio.2025.101634_bib47","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","article-title":"Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen","volume":"21","author":"Vardhana","year":"2020","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.mtbio.2025.101634_bib48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.immuni.2019.12.007","article-title":"Regulatory T cells restrain interleukin-2- and blimp-1-dependent acquisition of cytotoxic function by CD4 T cells","volume":"52","author":"\u015aledzi\u0144ska","year":"2020","journal-title":"Immunity"},{"issue":"16","key":"10.1016\/j.mtbio.2025.101634_bib49","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1158\/0008-5472.CAN-21-4141","article-title":"Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade","volume":"82","author":"Jenkins","year":"2022","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.mtbio.2025.101634_bib50","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41590-020-0793-3","article-title":"Disturbed mitochondrial dynamics in CD8(+) TILs reinforce T cell exhaustion","volume":"21","author":"Yu","year":"2020","journal-title":"Nat. Immunol."},{"issue":"87","key":"10.1016\/j.mtbio.2025.101634_bib51","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq2424","article-title":"Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8(+) T cell metabolic fitness and function in tumors","volume":"8","author":"Yang","year":"2023","journal-title":"Sci Immunol"},{"issue":"13","key":"10.1016\/j.mtbio.2025.101634_bib52","doi-asserted-by":"crossref","DOI":"10.1172\/JCI162530","article-title":"T-BET and EOMES sustain mature human NK cell identity and antitumor function","volume":"133","author":"Wong","year":"2023","journal-title":"J. Clin. Investig."},{"issue":"12","key":"10.1016\/j.mtbio.2025.101634_bib53","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1038\/ni1268","article-title":"Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin","volume":"6","author":"Intlekofer","year":"2005","journal-title":"Nat. Immunol."},{"issue":"7","key":"10.1016\/j.mtbio.2025.101634_bib54","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1016\/j.cell.2020.10.046","article-title":"Human T-bet governs innate and innate-like adaptive IFN-\u03b3 immunity against mycobacteria","volume":"183","author":"Yang","year":"2020","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.mtbio.2025.101634_bib55","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/ni.2059","article-title":"T-bet in disease","volume":"12","author":"Lazarevic","year":"2011","journal-title":"Nat. Immunol."},{"issue":"6","key":"10.1016\/j.mtbio.2025.101634_bib56","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/ana.26920","article-title":"Pathogenic potential of eomesodermin-expressing T-helper cells in neurodegenerative diseases","volume":"95","author":"Kanazawa","year":"2024","journal-title":"Ann. Neurol."},{"issue":"7980","key":"10.1016\/j.mtbio.2025.101634_bib57","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41586-023-06498-3","article-title":"Spatial predictors of immunotherapy response in triple-negative breast cancer","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"}],"container-title":["Materials Today Bio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006425001929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590006425001929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:45:58Z","timestamp":1762634758000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590006425001929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":57,"alternative-id":["S2590006425001929"],"URL":"https:\/\/doi.org\/10.1016\/j.mtbio.2025.101634","relation":{},"ISSN":["2590-0064"],"issn-type":[{"value":"2590-0064","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxymatrine and astragaloside IV co-loaded liposomes: Scale-up purposes and their enhancement of anti-PD-1 efficacy against breast cancer","name":"articletitle","label":"Article Title"},{"value":"Materials Today Bio","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mtbio.2025.101634","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101634"}}